The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
Abstract
PURPOSE: To evaluate the antitumor activity and toxicity of a new steroidal aromatase inactivator, exemestane, in postmenopausal women with metastatic breast cancer who had progressive disease (PD) after treatment with a nonsteroidal aromatase inhibitor. PATIENTS AND METHODS: In this phase II trial, eligible patients were treated with exemestane 25 mg daily (n = 241) followed, at the time PD was determined, by exemestane 100 mg daily (n = 58). RESULTS: On the basis of the intent-to-treat analysis by independent review, exemestane 25 mg produced objective responses in 6.6% of patients (95% confidence interval [CI], 3.8% to 10.6%) and overall success (complete response + partial response + no change for 24 weeks or longer) in 24.3% (95% CI, 19.0% to 30.2%). The median durations of objective response and overall success were 58.4 weeks (95% CI, 49.7 to 71.1 weeks) and 37.0 weeks (95% CI, 35.0 to 39.4 weeks), respectively. Increasing the dose of exemestane to 100 mg upon the development of PD produced one partial response (1.7%; 95% CI, 0.0% to 9.2%). Both dosages were well tolerated and were discontinued because of adverse events in only 1.7% of patients. CONCLUSION: Exemestane 25 mg once daily seems to be an attractive alternative to chemotherapy for the treatment of patients with metastatic breast cancer after multiple hormonal therapies have failed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Self-citationTamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Hortobagyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 781
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., BLOMQVIST, C. P., Vogel, C. L., EIERMANN, W., Wolter, J. M., Steinberg, M., Webster, A., et al. (1998) · PubMed · Cited by 417
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P., & Lønning, P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.531 · Cited by 336
Self-citationGeisler, J., King, N. C., Anker, G. B., Ornati, G., di Salle, E., Lønning, P. E., & Dowsett, M. (1998) · PubMed · Cited by 314
Self-citationDowsett, M., Jones, A. L., Johnston, S. R. D., Jacobs, S., Trunet, P. F., & Smith, I. E. (1995) · PubMed · Cited by 238
Brodie, A. M. H., Garrett, W. M., Hendrickson, J. R., Tsai-Morris, C.-H., Marcotte, P. A., & Robinson, C. H. (1981) · Steroids · doi:10.1016/0039-128x(81)90087-8 · Cited by 215
Research works printed but not linked: 5
- 10.1002/(SICI)1097-0142(19970601)79:11<2137::AID-CNCR11>3.0.CO;2-X · doi:10.1002/(sici)1097-0142(19970601)79:11<2137::aid-cncr11>3.0.co;2-x
- 10.1200/JCO.1994.12.8.1639 · doi:10.1200/jco.1994.12.8.1639
- Garcia-Giralt E, Ayme Y, Carton M, et al: Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat 24:139,1993-145, · doi:10.1007/bf01961246
- 10.1002/(SICI)1097-0142(19970715)80:2<218::AID-CNCR8>3.0.CO;2-P · doi:10.1002/(sici)1097-0142(19970715)80:2<218::aid-cncr8>3.0.co;2-p
- Geisler J, Lundgren S, Berntsen H, et al: Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83:2687,1998-2693, · doi:10.1210/jc.83.8.2687
Cited by
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Self-citationAromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
Self-citationChia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5822 · Cited by 513
Aromatase Inhibitors in the Treatment of Breast Cancer
Brueggemeier, R. W., Hackett, J. C., & Diaz-Cruz, E. S. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0015 · Cited by 484
Metadata
- Authors
- Lønning, P. E., Bajetta, E., Murray, R., Tubiana-Hulin, M., Eisenberg, P. D., Mickiewicz, E., Celio, L., Pitt, P., Mita, M., Aaronson, N. K., Fowst, C., Arkhipov, A., di Salle, E., Polli, A., & Massimini, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-06-11
- Volume
- 18
- Issue
- 11
- Pages
- 2234-2244
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1848530042
- Cited by
- 316
- References
- 25
- FWCI
- 26.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. https://app.cochat.ai/papers/10.1200/jco.2000.18.11.2234
- The paper
- Lønning, P. E., Bajetta, E., Murray, R., Tubiana-Hulin, M., Eisenberg, P. D., Mickiewicz, E., Celio, L., Pitt, P., Mita, M., Aaronson, N. K., Fowst, C., Arkhipov, A., di Salle, E., Polli, A., & Massimini, G. (2000). Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.11.2234
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.